Hims vs Willow: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Hims beats Willow overall, scoring 7.9/10 vs 7.5/10. Hims is more affordable at $199/mo vs $299/mo. Choose Hims for men who want a well-known publicly-traded brand and fda-appr. Choose Willow for users who want comprehensive clinical support with flexibili.
A side-by-side look at Hims and Willow to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
Hims
#9 of 52The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy (injection and pill) and Ozempic through a direct Novo Nordisk partnership, alongside their existing compounded semaglutide program. Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026), significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28%, the highest 1-star rate in our table, clustered around subscription/billing complaints.
Visit HimsWillow
#24 of 52Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only, Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.
Visit Willow| Feature | Hims | Willow |
|---|---|---|
| Our Score | 7.9/10 | 7.5/10 |
| Starting Price | $199/mo | $299/mo |
| Medication Type | Both | Compounded |
| Insurance Accepted | No | No |
| Best For | Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership, but should know going in that Hims' customer-experience signal is weaker than smaller competitors | Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes |
| Ranking | #9 | #24 |
| Get started | Visit Hims | Visit Willow |
Pros & Cons Compared
Hims
Pros
- +Publicly traded company (NYSE: HIMS), SEC-filed financials, regulatory accountability that private competitors don't have.
- +2026 Novo Nordisk partnership, FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
- +$199/mo all-inclusive for compounded semaglutide, including consultations and shipping.
- +Polished app and web experience, among the best user interfaces in men's telehealth.
- +8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461), significant real-world adoption.
Cons
- −Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026), significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
- −28% of Trustpilot reviews are 1-star, the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
- −Hims reviews span ALL their products (ED, hair loss, mental health, weight loss), not just GLP-1. But the rating still applies because most users don't separate experiences by product.
- −'Hims Oral Kit' is NOT a GLP-1, it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Easy to confuse with their compounded semaglutide. Read the product page carefully before signing up.
- −Brand Wegovy at $599/mo is not competitive with LillyDirect/NovoCare cash prices or with Hers ($149/mo for the same product via the same Novo partnership).
- −Generic high-volume support, large patient base means less personalized attention than smaller competitors.
Willow
Pros
- +Includes monthly provider check-ins and dose adjustments at no extra cost
- +Offers both injectable AND oral compounded semaglutide, one of few platforms with a daily oral tablet option
- +$299/mo all-in for compounded semaglutide with monthly provider support
- +90%+ patient retention rate after 3 months per their published outcomes data
Cons
- −Compounded-only, no brand-name Wegovy or Zepbound through the platform
- −Tirzepatide pricing reaches $499-$524 at higher doses, starting dose is $399/mo
- −Cash-pay only, no insurance billing, though they provide superbills for FSA/HSA
- −Founded in 2024, less track record than Ro or Hims, though growth has been fast
Our Verdict
Hims edges out Willow with a score of 7.9/10 vs 7.5/10. If budget is your priority, Hims starts at $199/mo compared to Willow's $299/mo. Hims offers both brand-name and compounded medications, giving you more flexibility. Choose Hims if you want: men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership, but should know going in that hims' customer-experience signal is weaker than smaller competitors. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.
Still undecided? Editor's Featured Pick
Yucca Health
$146/mo · 7.7/10 · Compounded
If neither Hims nor Willow feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is Yucca Health. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $146/mo that stays the same at every dose.
Read Full Reviews
Related comparisons
Other matchups readers comparing Hims or Willow tend to look at next.
- Hims vs MEDVi$179/mo
- Hims vs Hers$199/mo
- Hims vs Shed$199/mo
- Willow vs MyStart Health$299/mo
- Willow vs Direct Meds GLP-1$297/mo
- Willow vs DudeMeds$149/mo
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.